Gene alterations of TTN (coding for Titin, 1225% of DCM), LMNA (coding for Lamina/C, 48% of DCM), DES , VLC and FLNC (coding for cytoskeletal proteins, each around 1% of DCM) significantly contribute to the DCM phenotype [105]
2026 Europe PMC From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management
Frequently Asked Questions About BPC-157 What is BPC-157 used for in research?+ What purity is Koi's BPC-157?+ How do I reconstitute BPC-157 peptide?+ What is the CAS number for BPC-157?+ How should BPC-157 be stored?+ Is BPC-157 for human use?+ Does BPC-157 come with a Certificate of Analysis?+ What is BPC-157's FDA and compounding status?+ Stock your lab with Koi Research-grade peptides made in the USA, third-party tested, with public lot-matched COAs
It is designed for FIP treatment in cats weighing under 2.5 kg where secondary systemic complications anaemia, neurological involvement, appetite suppression, or immune compromise are present alongside the primary FIP diagnosis
Specifically, its inflammation in the subtalar joint where your ankle bone (talus) meets your heel bone (calcaneus)
The goal is creating resilient tissue, not just pain-free tissue
